Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool May 28, 2010 Brian Orelli	This Drug Doesn't Work. But All Is Not Lost. Novartis cancer drug fails one trial, but there's still hope.
The Motley Fool October 27, 2010 Ralph Casale	Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment.
The Motley Fool August 26, 2009 Brian Orelli	This One's Growing Through the Recession Sales at Myriad Genetics increased 40% in its recently completed second half of its fiscal year, even if that was a slowdown from the 55% increase in the first half.
The Motley Fool July 9, 2008 Brian Lawler	Predicting More Good News From Invitrogen Invitrogen gets a positive review from the FDA for one of its tests.
The Motley Fool March 31, 2010 Brian Orelli	When One Patent Means So Much The loss of patents on genes could have far-reaching consequences for drug companies.
The Motley Fool April 28, 2009 Brian Orelli	Headline? Bad! Unexpected? No! For a company that only has one drug on the market, stopping a failing phase 3 clinical trial that's designed to expand the market of that drug is usually a major blow. But Onyx Pharmaceuticals was able to shrug it off.
The Motley Fool August 23, 2005 W.D. Crotty	A Myriad of Revenue Myriad Genetics reports a solid fourth-quarter and fiscal year. Is this high-risk biotech concern worth a look?
Chemistry World August 22, 2014 Phillip Broadwith	Illumina targets cancer diagnostics Genetic sequencing heavyweight Illumina has partnered with three major pharmaceutical firms in a bid to develop a universal sequencing-based oncology test system.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool February 15, 2011 Rich Smith	What's Behind the Run-Up at Exelixis? One word: earnings. Shares of this tiny drug developer have taken off like a rocket.
The Motley Fool June 2, 2009 Brian Orelli	Pfizer: If You Can't Beat 'Em, Join 'Em Sutent fails. Again.
The Motley Fool April 11, 2011 Brian Orelli	A Double Dose of Trouble for Big Pharma? Pfizer's Sutent and Novartis's Afinitor head in front of an FDA advisory panel.
BusinessWeek May 9, 2005 Catherine Arnst	Genentech's Lessons For Big Pharma The biotech company focuses on science -- not marketing, acquisitions, or patents.
The Motley Fool November 12, 2007 Charly Travers	The Value of Myriad's Genes Myriad Genetics is unique in the biotech industry because it has a profitable diagnostics business to support its drug research and development efforts, as well as attractive prospects in its pipeline. Investors, take note.
The Motley Fool April 27, 2011 Brian Orelli	Falling Into the Zaltrap Lung cancer out, colon cancer in phase 3 clinical trial for Regeneron Pharmaceuticals' new drug.
The Motley Fool February 28, 2011 Brian Orelli	Rare Diseases, Big Opportunity "Orphan" drugs to keep your eye on.
The Motley Fool July 24, 2009 Brian Orelli	Juicing Up the Earnings Report How did Celgene turn an earnings release that met analysts' expectations while lowering revenue guidance on one of its drugs into an 18.6% increase in share price yesterday?
The Motley Fool February 2, 2010 Brian Orelli	Shaking Up the Biotech Industry A judge will decide if genes are patentable or not.
BusinessWeek May 23, 2005 Catherine Arnst	If It Works for Breast Cancer... Studies are under way to see if promising strategies used against breast cancer can be used to fight other killers, such as lung, colon, and prostate cancer.
The Motley Fool March 16, 2011 Brian Orelli	Different Name, Same Great Results Incyte and Novartis' ruxolitinib passes another clinical trial.
The Motley Fool July 12, 2010 Ryan McBride	Synta Pharma CEO Trumpets New Top Cancer Drug Synta Pharmaceuticals has been climbing back from one of the Boston area's highest-profile clinical trial failures of 2009.
The Motley Fool June 2, 2011 Luke Timmerman	Infinity Dares to Think Big Against Pancreatic Cancer, Prepares to Show Early Results This Weekend Infinity Pharmaceuticals' top execs sometimes get strange looks when they say they are developing a new drug for pancreatic cancer. Is this a smart use of the company's time and resources?
The Motley Fool March 21, 2011 Brian Orelli	Let's See Some Data, Curis Curis investors seem to have shrugged off the multiple unknowns and embraced the potential for the company's skin cancer drug.
Salon.com July 14, 2000 Arthur Allen	The cancer study bombshell that wasn't Were the New York Times and the Washington Post writing about the same New England Journal of Medicine article?
The Motley Fool April 13, 2011 Brian Orelli	Drug Duo Escapes Advisory Panel Unharmed Pfizer and Novartis are on their way to expanding their cancer drug indications.
Fast Company David Lumb	Sites That Sell Cancer Gene Tests Don't Tell Customers The Whole Story, Study Finds Consumer tests that analyze DNA from tumors in order to help personalize a patient's treatment are in something of a Wild West period.
The Motley Fool March 25, 2011 Brian Orelli	Pfile Pfizer Under "Potential" Researchers reported promising finding from a clinical trial of Pfizer's new drug, CP-870,893, in pancreatic cancer patients in the most recent issue of the journal Science.
The Motley Fool December 14, 2010 Brian Orelli	Another Mishap for a Drugmaker That Can't Afford It Eli Lilly puts cancer drug tasisulam on a clinical hold.
The Motley Fool February 24, 2011 Brian Orelli	Profit From Personalized Medicine Pfizer's drug works well, but consider these companies instead.
The Motley Fool February 8, 2011 Esterhuizen & Sellitti	Finding a Cure for Cancer: The Option Market's Favorite Ideas What cancer stocks are investors taking seriously?: Allos Therapeutics... China Medical Technologies... Delcath Systems... Myriad Genetics... ZIOPHARM...
The Motley Fool January 22, 2010 Brian Orelli	Pfizer's Great Data Won't Do Much The full data from a clinical trial testing Pfizer's Sutent in pancreatic cancer was truly amazing. Unfortunately, it's not going to do very much for the stock or Pfizer's bottom line.
The Motley Fool June 30, 2010 Ryan McBride	Reports: Biogen Picks Exelixis Chief George Scangos as New CEO George Scangos, a microbiologist by training, has been CEO of the South San Francisco-based cancer drug developer Exelixis since 1996, and takes over at Biogen immediately.
BusinessWeek May 27, 2010 Pettypiece & Gibson	Training the Immune System to Fight Cancer Bristol-Myers' new melanoma drug may be a "game changer."
The Motley Fool March 5, 2010 Brian Orelli	How to Replace $6.1 Billion in Lost Revenue It's not easy, but Bristol-Myers will give it a shot.
Managed Care March 2007 Martin Sipkoff	Managing Cancer Treatment Begins Before Diagnosis Health plans are increasingly involved in promoting the lifestyle changes that help their members avoid cancer, and are increasingly involved in clinical trials if prevention fails.
The Motley Fool June 9, 2010 Brian Orelli	ASCO Pops and Drops Themes and company news from the annual meeting of the American Society of Clinical Oncology.
Chemistry World January 30, 2015 Rebecca Trager	Myriad calls a ceasefire in court battle over cancer gene tests Myriad Genetics has ended its bid to prevent other companies from producing tests for genetic mutations associated with an increased risk of breast and ovarian cancer that it owned patents on.
The Motley Fool June 30, 2004 Mike Cianciolo	1-800-Flowers.com Droops The online flower and gift retailer projects lower-than-anticipated sales for the fourth quarter.
BusinessWeek April 25, 2005 Gene G. Marcial	Affymetrix: A Lab Boost The GeneChip can reduce the risk of adverse reactions to drugs by checking the recipient's DNA against the drug's profile. Some people are optimistic about the company's stock.
The Motley Fool August 22, 2006 Brian Gorman	NICE Unkind to Biotech Developments in the U.K.'s drug coverage may hurt U.S. biotechs. Biotech investors, keep your eyes on this issue.
The Motley Fool September 28, 2006 Brian Lawler	Myriad Moves Forward The biotech's new cancer candidate passes phase 1 trials. Investors should take note, and make room for Myriad on their radar screens.
The Motley Fool September 2, 2005 Rich Smith	Ciena Sings Same Song This quarter's gross showed a dramatic improvement not just over last year's, but over the previous two quarters of the fiscal year. But the telecom equipment maker is still losing money hand over fist. Investors, take note.
The Motley Fool June 15, 2010 Brian Orelli	Just Enough to Give Investors Hope Hitting a secondary endpoint means all is not lost for Onyx's lung cancer drug.
The Motley Fool June 30, 2010 Brian Orelli	When Researchers Attack, Investors Lose Drug investors have to watch out for a lot of things that can change their stock's price: earnings reports, clinical trial results, competitor's results, and FDA decisions.
The Motley Fool November 29, 2011 Brian Orelli	Winners and Losers of Roche's Avastin Woes What the FDA giveth, the FDA can taketh away.
The Motley Fool August 19, 2004 Rich Smith	Daktronics Out of Focus? Earnings and revenues rise, but a few questions arise as well.
The Motley Fool July 9, 2004 Mike Cianciolo	No Place for Children The children's clothing retailer drops on projected second-quarter losses.
The Motley Fool April 7, 2011 Brian Orelli	Drug Approved! But Where's the Name? AstraZeneca prepares to cash in on a minuscule market.
Chemistry World September 2, 2014 Phillip Broadwith	Exelexis slashes workforce by 70% The move follows poor results from a clinical trial of its cancer drug Cometriq (cabozantinib) in men with metastatic castration-resistant prostate cancer.
The Motley Fool May 8, 2009 Brian Orelli	Investing Against Breast Cancer Many companies are interested in both a cure and a large lucrative market. Which are the best investments now in this sector?